Back to search results

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Ovarian Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Loyola University Medical Center, Maywood, Illinois, United States

    Contact: Study coordinator (Patrick Stiff, MD) · pstiff@lumc.edu · 708-327-3148
    Contact: Study coordinator (Jennifer Guevara, RN) · jguevara@luc.edu · 708-327-3239
    Ronald Potkul, MD (Sub-investigator)
    Contact: Principal Investigator (Margaret Liotta, MD)
    Abigal Winder, MD (Sub-investigator)
Study leads

  • Patrick L Stiff, MD

    Principal Investigator

    Loyola University

View source on ClinicalTrials.gov(opens in a new tab)